Sei Investments Co. lifted its holdings in shares of Haemonetics Co. (NYSE:HAE) by 29.7% in the first quarter, Holdings Channel reports. The institutional investor owned 13,545 shares of the medical instruments supplier’s stock after buying an additional 3,103 shares during the period. Sei Investments Co.’s holdings in Haemonetics were worth $990,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Alpine Woods Capital Investors LLC acquired a new position in shares of Haemonetics during the 1st quarter worth about $236,000. Tyers Asset Management LLC boosted its stake in shares of Haemonetics by 20.7% during the 4th quarter. Tyers Asset Management LLC now owns 4,192 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 720 shares during the last quarter. ARP Americas LP acquired a new position in shares of Haemonetics during the 1st quarter worth about $341,000. Lazard Asset Management LLC acquired a new position in shares of Haemonetics during the 4th quarter worth about $274,000. Finally, Xact Kapitalforvaltning AB acquired a new position in shares of Haemonetics during the 4th quarter worth about $308,000. Institutional investors own 99.31% of the company’s stock.
A number of equities analysts have recently commented on HAE shares. ValuEngine upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Morgan Stanley increased their price objective on shares of Haemonetics from $77.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 9th. Zacks Investment Research downgraded shares of Haemonetics from a “strong-buy” rating to a “sell” rating in a research note on Wednesday, April 11th. Jefferies Financial Group increased their price objective on shares of Haemonetics from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, June 14th. Finally, TheStreet upgraded shares of Haemonetics from a “c+” rating to a “b” rating in a research note on Tuesday, May 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $87.83.
Shares of NYSE:HAE opened at $89.40 on Friday. Haemonetics Co. has a 52-week low of $38.47 and a 52-week high of $96.84. The stock has a market capitalization of $4.62 billion, a P/E ratio of 47.81, a PEG ratio of 4.01 and a beta of 0.93. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.35 and a quick ratio of 0.94.
Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.43. Haemonetics had a net margin of 5.04% and a return on equity of 12.71%. The business had revenue of $233.55 million during the quarter, compared to the consensus estimate of $226.63 million. During the same period last year, the business posted $0.39 EPS. Haemonetics’s revenue was up 2.4% on a year-over-year basis. sell-side analysts expect that Haemonetics Co. will post 2.21 EPS for the current year.
In related news, VP Dan Goldstein sold 518 shares of the firm’s stock in a transaction dated Friday, April 6th. The shares were sold at an average price of $54.65, for a total value of $28,308.70. Following the completion of the sale, the vice president now directly owns 4,002 shares in the company, valued at approximately $218,709.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Simon sold 1,941 shares of the firm’s stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $92.73, for a total transaction of $179,988.93. The disclosure for this sale can be found here. Insiders sold a total of 19,090 shares of company stock valued at $1,496,044 over the last quarter. 1.04% of the stock is currently owned by company insiders.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.